CDKN2A and head and neck squamous cell carcinoma: However, the significance of the data has been called into question because of the limited cohort of p16-positive patients across subsites and the high rates of p16 positivity outside the oropharynx, as well as by the fact that pantitumumab has not prolonged survival in HNSCC in any trial in any line of therapy.